Last reviewed · How we verify
Arteriosclerotic Parkinsonism
Approved treatments
- Artane
- Cogentin · University of Southern California
- Artane
- Kemadrine
- Akineton · AbbVie
- Gocovri · Endo
- Cogentin
- GOCOVRI · Oregon Health and Science University
- Amantadin · Centre Hospitalier Universitaire de Nice
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Arteriosclerotic Parkinsonism patent landscape — cliff calendar, originator estates, attackable patents
- Arteriosclerotic Parkinsonism treatment landscape brief
- Arteriosclerotic Parkinsonism treatment updates RSS
Frequently asked questions about Arteriosclerotic Parkinsonism
What drugs treat Arteriosclerotic Parkinsonism?
Tracked treatments include Artane, Cogentin, Kemadrine, Akineton, Gocovri, GOCOVRI, Amantadin.
What is the treatment for Arteriosclerotic Parkinsonism?
Standard treatment for Arteriosclerotic Parkinsonism includes Artane, Cogentin, Kemadrine, Akineton, Gocovri. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Arteriosclerotic Parkinsonism patent cliff · Arteriosclerotic Parkinsonism CI report
- Treatment: Artane
- Treatment: Cogentin · University of Southern California
- Treatment: Artane
- Treatment: Kemadrine
- Treatment: Akineton · AbbVie
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing